Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Overview
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Companies Involved in Therapeutics Development
G3 Pharmaceuticals Inc
Galectin Therapeutics Inc
Galecto Biotech AB
Glycomantra Inc
GlycoMimetics Inc
Immutics Inc
MandalMed Inc
Proteris Biotech Inc
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Drug Profiles
belapectin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GB-0139 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GB-1211 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GB-2064 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GM-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GM-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GMCT-04 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GMI-1757 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GRMD-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GRMD-04 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMT-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protearin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombint Protein to Inhibit Galectin-3 for Myocardial Fibrosis and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Galectin-3 for Cardiovascular Disease, Fibrosis and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit LGALS3 for Cardiovascular and Genito Uriry System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TFD-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Dormant Products
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Discontinued Products
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Product Development Milestones
Featured News & Press Releases
Feb 04, 2020: Galectin Therapeutics president and CEO Dr. Harold Shlevin to present at the 3rd Global SH Congress 2020
Dec 09, 2019: Galectin Therapeutics phase 2 SH cirrhosis clinical trial results on belapectin (GR-MD-02) published in gastroenterology
Dec 05, 2019: Galectin Therapeutics plans adaptively designed phase 3 SH-RX clinical trial in SH Cirrhosis
Nov 11, 2019: Galectin Therapeutics reaches agreement with Siemens Healthineers to collaborate on SH and Liver Fibrosis
Nov 05, 2019: Additiol Ad Hoc alysis of ELF data from Galectin Therapeutics SH-CX phase 2 clinical trial to be highlighted in poster presentation at the 2019 AASLD Liver Meeting
Sep 17, 2019: Galectin Therapeutics and Providence Cancer Institute receive patent on the use of Belapectin (GR-MD-02) in Cancer Immunotherapy
Aug 05, 2019: Galectin Therapeutics submits phase 3 SH-RX protocol in sh Cirrhosis to FDA
Mar 22, 2019: Providence Cancer Institute to Present Findings on GR-MD-02 at the 2019 Keystone Symposia on Molecular and Cellular Biology
Dec 04, 2018: GlycoMimetics presents poster at 60th ASH Annual Meeting highlighting preclinical data on GMI-1757
Nov 05, 2018: Data collected by Exalenz Bioscience in Galectin Therapeutics phase 2 SH-CX trial of GR-MD-02 to be presented at AASLD Annual Meeting
Sep 20, 2018: Galectin Therapeutics announces positive prelimiry results from phase 1b clinical trial of GR-MD-02 and KEYTRUDA in advanced melanoma and expansion of the Trial
Jul 18, 2018: GlycoMantra received SBIR Phase 1 grant from the NCI (NIH)
Jun 27, 2018: Galectin Therapeutics Receives Patent for GR-MD-02 Patent for Method and Treatment of Pulmory Fibrosis
Jun 12, 2018: Galectin Therapeutics Announces New CEO
Jun 04, 2018: Galectin Therapeutics Announces Richard E. Uihlein Elected Chairman of the Board
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020


List of Tables


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by G3 Pharmaceuticals Inc, H1 2020
Pipeline by Galectin Therapeutics Inc, H1 2020
Pipeline by Galecto Biotech AB, H1 2020
Pipeline by Glycomantra Inc, H1 2020
Pipeline by GlycoMimetics Inc, H1 2020
Pipeline by Immutics Inc, H1 2020
Pipeline by MandalMed Inc, H1 2020
Pipeline by Proteris Biotech Inc, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Dormant Products, H1 2020 (Contd..2), H1 2020
Discontinued Products, H1 2020